Slide 1: ARJO Q2 Report 2025: Continued healthy customer demand
ARJO Q2 REPORT 2025 Continued healthy customer demand Niclas Sjöswärd, Interim CEO Christofer Carlsson, Interim CFO 1
Slide 2: Continued healthy customer demand
Continued healthy customer demand • Net sales growth in line with full year target, with strong development in the US Net sales Gross organic growth margin • Further strengthened order book • Gross profit almost in line with last year, despite tariffs 3.0% 43.4% and negative currency impact • Cost e
Slide 3: North America Global Sales
+10.5% -1.8% North America Global Sales Double-digit growth in the US Western Europe, -2.4% • Solid demand within Rental and Service • Weaker quarter in UK • Uptick in Patient Handling with good • Good development in large order book markets incl. France, Germany and Italy Another solid quarter in C
Slide 4: Gross margin just behind last year's level
Gross margin just behind Gross profit bridge – Q2 2025 vs. Q2 2024 (MSEK) last year’s level Margin development x Margin (Percent) x (Percentage point) • Positive impact from product and geographic mix somewhat offset by US tariffs impact and 43.6% N/A +0.1 p.p. -0.2 p.p. 43.4% negative currency effe
Slide 5: Improved cost control
Improved cost control Adj. EBIT bridge – Q2 2025 vs. Q2 2024 (MSEK) x Margin (Percent) • Adj. EBIT decreasing vs. Q2 2024, mainly due to FX and tariffs 8.3% 7.8% • Stable underlying business – positive trend -25 when adjusting for currency and tariffs 14 5 -18 • Visible effects from accelerated cost
Slide 6: Q2 working capital and operating cash flow
Q2 working capital and operating cash flow Slight increase in working Operating cash flow impacted by higher capital days inventory and temporary VAT effect Working capital days – Q1.22-Q2.25 Operating cash flow – Q1.22-Q2.25 Working capital days* Operating cash flow (MSEK)* 734 565 99 95 96 96 95 5
Slide 7: Q2 net debt and leverage
Q2 net debt and leverage Seasonal variance further enhanced Increase in leverage due to strategic by higher investments investments and FX headwind Net debt – Q1.22-Q2.25 Leverage – Q1.22-Q2.25 Net debt, incl. IFRS16 (BSEK) Net debt / Adj EBITDA, multiple (R12)* 5.3 5.1 5.1 5.2 5.0 2.8 2.8 2.8 4.7 2
Slide 8: Outlook
Outlook 2025 Organic net sales growth for 2025 is expected to be within the Group’s target interval of 3-5% 8
Slide 9: Q2 key takeaways
Q2 key takeaways • Continued healthy demand – growth in line with target and further strengthened order book • US and Patient Handling standing out positively in Q2 • Cost efficiency measures paying off – focus to continue • When adjusted for currency and tariffs, underlying profitability develops w
Slide 10: Q&A
Q&A
Slide 11: Financial calendar / Further questions
Financial calendar Interim Report Jan-Sep 2025 October 22, 2025 Year-end Report 2025 January 30, 2026 Annual and Sustainability Report 2025 March-April 2026 Interim Report Jan-Mar 2026 April 29, 2026 Annual General Meeting 2026 April 29, 2026 Further questions Maria Nilsson EVP, Communication & Publ
Slide 12: Forward looking information
Forward looking information This document contains forward-looking information based on the current expectations of Arjo’s management. Although management deems that the expectations presented by such forward-looking information are reasonable, no guarantee can be given that these expectations will
Slide 13: Empowering Movement
aifJjJoO EMPOWERING MOVEMENT